FDA Turmoil, Ozempic Costs & Autism Diagnoses: Health News Roundup

Morning Rounds brings you the latest from the intersection of health, medicine, and policy. Today, we’re following the departure of a key figure at the Food and Drug Administration, examining the potential for lower costs for popular weight loss medications, and exploring the complex factors driving rising autism diagnoses.

Fresh Leadership Change at the FDA

Dr. Vinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research (CBER) at the FDA at the end of April, marking his second departure from the agency. STAT News reports that Prasad, an oncologist, previously left the position in July of last year before being rehired weeks later. His tenure has been marked by controversy and a series of surprising drug rejections, raising concerns within the biopharmaceutical industry. The FDA has also seen a significant decrease in public advisory committee meetings – a 72% drop under the Trump administration – with some officials citing cost and efficiency as reasons for the decline. This reduction in transparency is worrying rare disease advocates, particularly given the recent wave of unexpected decisions regarding drug approvals. More on this developing story from STAT.

The Promise of Affordable Ozempic

The high cost of weight loss medications like Ozempic and Wegovy remains a significant barrier to access for many. Novo Nordisk recently announced list price reductions, halving the current cost to $675, and direct-to-consumer prices are even lower. However, a latest analysis suggests that generic versions of semaglutide, the active ingredient in these drugs, could be dramatically cheaper. As patents expire in countries like India, China, Canada, Brazil, and Turkey, researchers estimate that generics could be manufactured for as little as $28 per person per year. Ed Silverman at STAT details this potential shift in affordability, which could have a substantial impact on individuals with obesity and type 2 diabetes. This potential price drop highlights the importance of generic drug competition in lowering healthcare costs.

Understanding the Rise in Autism Diagnoses

Rates of autism diagnoses continue to rise in the United States, and pediatrician Lawrence Diller suggests a contributing factor is the financial incentive for parents to seek a diagnosis. STAT News reports that many parents are seeking an autism diagnosis to gain insurance coverage for applied behavioral analysis (ABA) therapy, a treatment shown to benefit children with autism and other developmental delays. Insurance companies typically only cover ABA therapy for children who meet the criteria for an autism diagnosis, leading to a situation where a year of treatment can cost families $70,000 out of pocket. Diller argues that broader financial support and services for all toddlers and preschoolers, regardless of diagnosis, are needed to address this desperation for an autism label. The Centers for Disease Control and Prevention (CDC) provides information on autism spectrum disorder, including prevalence data and resources for families.

Corporate Influence in Oregon Hospitals Sparks Backlash

A new law in Oregon aimed at curbing corporate takeovers in healthcare is facing its first major test. PeaceHealth, a hospital operator, is replacing a long-standing local physicians group in its emergency rooms with Atlanta-based ApolloMD. This move has sparked protests and petitions from doctors, nurses, and community members who fear the corporatization of healthcare. Tara Bannow at STAT reports that nationwide, less than half of emergency room visits are handled by physician-owned groups, and only one in three by doctors employed directly by the hospital. This trend raises concerns about the impact of corporate influence on patient care and the autonomy of medical professionals.

Helping Patients Understand Risk: A New Approach

Communicating risk effectively to patients is a crucial part of medical decision-making. A recent article in JAMA Insights highlights the importance of providing numerical comparisons to help patients evaluate the risks and benefits of different treatment options. For example, instead of simply stating a patient’s risk of developing cancer is 6%, clinicians can provide context by comparing that risk to the average population risk. The authors suggest that offering statistics about alternatives can empower patients to make more informed decisions and feel more comfortable following recommendations. The full article is available in JAMA.